Date	Price Target	Rating	Analyst
9/17/2025	$3.00	Overweight	Barclays
11/7/2024		Mkt Outperform → Mkt Perform	JMP Securities
8/1/2024		Buy → Neutral	BTIG Research
7/31/2024	$18.00 → $5.00	Buy → Neutral	B. Riley Securities
7/31/2024		Buy → Neutral	Guggenheim
5/10/2024	$24.00 → $8.00	Outperform → Market Perform	BMO Capital Markets
5/10/2024	$29.00 → $7.00	Buy → Hold	Stifel
5/10/2024		Buy → Hold	TD Cowen

More analyst ratings

FDA Approval for MARGENZA

12/20/20 4:31:01 PM ET

$MGNX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MGNX alert in real time by email

Biologic License Application (BLA): 761150
Company: MACROGENICS INC

Products on BLA 761150

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
MARGENZA	MARGETUXIMAB-CMKB	250MG/10ML(25MG/ML)	INJECTABLE;INJECTION	Prescription	None	TBD	No

Approval Date(s) and History, Letters, Labels, Reviews for BLA 761150

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
12/16/2020	ORIG-1	Approval		N/A		Label is not available on this site.

Get the next $MGNX alert in real time by email

Crush Q3 2025 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$MGNX

Date	Price Target	Rating	Analyst
9/17/2025	$3.00	Overweight	Barclays
11/7/2024		Mkt Outperform → Mkt Perform	JMP Securities
8/1/2024		Buy → Neutral	BTIG Research
7/31/2024	$18.00 → $5.00	Buy → Neutral	B. Riley Securities
7/31/2024		Buy → Neutral	Guggenheim
5/10/2024	$24.00 → $8.00	Outperform → Market Perform	BMO Capital Markets
5/10/2024	$29.00 → $7.00	Buy → Hold	Stifel
5/10/2024		Buy → Hold	TD Cowen

More analyst ratings

$MGNX
Press Releases

Fastest customizable press release news feed in the world

View All

MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference

ROCKVILLE, MD, Sept. 02, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that MacroGenics' President & Chief Executive Officer, Eric Risser, will present at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025, at 11:30am ET in New York, NY. A webcast of the above presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain an archived replay of the webcast on its website for 30 days. Abo

9/2/25 4:30:00 PM ET

$MGNX

Biotechnology: Pharmaceutical Preparations

Health Care

MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities

Newly-appointed President and CEO, Eric Risser, outlines strategic priorities for 2025 and 2026 Received $70 million upfront cash payment from Sagard Healthcare Partners under a royalty purchase agreement for ZYNYZ® Cash, cash equivalents and marketable securities of $176.5 million as of June 30, 2025; cash runway through first half of 2027 ROCKVILLE, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2025, and highlighted recent corporate progress. "Over the past s

8/14/25 4:01:00 PM ET

$MGNX

Biotechnology: Pharmaceutical Preparations

Health Care

MacroGenics Appoints Eric Risser as President and Chief Executive Officer

ROCKVILLE, MD, Aug. 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company developing innovative antibody-based therapeutics for the treatment of cancer, today announced that effective as of August 13, 2025, Eric Risser has been appointed President, Chief Executive Officer and to the Board of Directors. Mr. Risser has served as Chief Operating Officer at MacroGenics since 2022, overseeing several key company functions and has led the Company's corporate development efforts, which have generated over $1.6 billion in non-dilutive capital since inception. Mr. Risser succeeds Scott Koenig, M.D., Ph.D. who is stepping down after serving as Presi

8/13/25 4:01:00 PM ET

$MGNX

Biotechnology: Pharmaceutical Preparations

Health Care

$MGNX
Financials

Live finance-specific insights

View All

MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results

First patient dosed in LINNET Phase 2 study of lorigerlimab in ovarian and other gynecologic cancers Clinical update on LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPC, expected in second half of 2025 Advancement in portfolio of innovative ADC product candidates, including MGC026, MGC028 and MGC030 Cash, cash equivalents and marketable securities of $154.1 million as of March 31, 2025 ROCKVILLE, Md., May 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for

5/13/25 4:01:00 PM ET

$MGNX

Biotechnology: Pharmaceutical Preparations

Health Care

MacroGenics Announces Date of First Quarter 2025 Financial Results

ROCKVILLE, MD, May 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2025 after the market closes on Tuesday, May 13, 2025. The Company will not be hosting a conference call to discuss its financial results or corporate progress for the quarter ended March 31, 2025. The Company may resume its practice of hosting quarterly results conference calls in the future. About MacroGenics, Inc.MacroGenics (the Company) is a biopharm

5/6/25 4:30:00 PM ET

$MGNX

Biotechnology: Pharmaceutical Preparations

Health Care

MacroGenics Provides Update on Corporate Progress and 2024 Financial Results

Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating new LINNET Phase 2 study of lorigerlimab in ovarian cancerAdvancing multiple novel topoisomerase 1 inhibitor-based ADCs, including MGC026, MGC028 and MGC030Discontinuing further internal clinical development of vobra duo; exploring potential partneringCash, cash equivalents and marketable securities of $201.7 million as of December 31, 2024; cash runway extended into the second half of 2026Conference call scheduled for today at 4:30 p.m. ET  ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical com

3/20/25 4:02:38 PM ET

$MGNX

Biotechnology: Pharmaceutical Preparations

Health Care

$MGNX
Leadership Updates

Live Leadership Updates

View All

MacroGenics Appoints Eric Risser as President and Chief Executive Officer

8/13/25 4:01:00 PM ET

$MGNX

Biotechnology: Pharmaceutical Preparations

Health Care

MacroGenics Announces Leadership Transition

Scott Koenig, M.D., Ph.D., to step down as President and CEOBoard to initiate search process to identify new CEO ROCKVILLE, MD, Oct. 30, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that Scott Koenig, M.D., Ph.D., intends to step down as President and Chief Executive Officer early next year. The Company's Board of Directors has retained Heidrick & Struggles to lead a search process to identify its next Chief Executive Officer and has established a special committee of the Board to oversee the t

10/30/24 7:30:00 AM ET

$MGNX

Biotechnology: Pharmaceutical Preparations

Health Care

MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors

ROCKVILLE, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointment of Dr. Margaret A. Liu and Meenu Chhabra Karson to its Board of Directors, effective January 3, 2023. Dr. Liu will serve as a member of MacroGenics' Science and Technology Committee and Ms. Karson will serve as a member of the Company's Audit Committee. Following the appointment of Dr. Liu and Ms. Karson, MacroGenics' Board will comprise ten directors, nine of whom are independent. "We are delighted to have both Margaret and Meenu join Ma

1/4/23 4:30:00 PM ET

$MGNX

Biotechnology: Pharmaceutical Preparations

Health Care

FDA Approval for MARGENZA

Products on BLA 761150

Approval Date(s) and History, Letters, Labels, Reviews for BLA 761150

Original Approvals or Tentative Approvals

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $MGNX

FDA Approval for MARGENZA

Products on BLA 761150

Approval Date(s) and History, Letters, Labels, Reviews for BLA 761150

Original Approvals or Tentative Approvals

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $MGNX

$MGNX Press Releases

MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference

MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities

MacroGenics Appoints Eric Risser as President and Chief Executive Officer

$MGNX SEC Filings

SEC Form S-8 filed by MacroGenics Inc.

SEC Form 10-Q filed by MacroGenics Inc.

MacroGenics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$MGNX Insider Trading

Director Heiden William K bought $150,515 worth of shares (100,000 units at $1.51), increasing direct ownership by 909% to 111,000 units (SEC Form 4)

SEC Form 4 filed by Sr VP, Technical Ops Spitznagel Thomas

SEC Form 4 filed by Senior VP and General Counsel Peters Jeffrey Stuart

$MGNX FDA approvals